Get started
Work

Reply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer’

Year: 2013
Type: letter
Abstract: We thank Shamash and Sarker for their interest in our recent article ( Omlin et al, 2013 ). They make three comments: first, that the activity of diethylstilboestrol (DES) when combined with a corticosteroid such as dexamethasone (D) is increased compared to DES alone; second, that chemotherapy may re-induce sensitivity to a hormonal agent; finally, their experience in 11 patients who received the sequence of docetaxel followed by DES and D and then abiraterone acetate (AA) and prednisone. In this setting the activity of AA was limited, as indicated by a median progression-free survival (PFS) of 1.8 months (range 0.6–8.1).
DOI: 10.1038/bjc.2013.737
Authors: A Omlin, C J Pezaro, S Zaidi, D Lorente, D Mukherji, D Bianchini, R Ferraldeschi, S Sandhu, D Dearnaley, C Parker, N Van As, J S de Bono, G Attard
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,190
Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Exelixis, Cancer Research UK, National Institute for Health and Care Research, Astellas Pharma, Ipsen, Genentech, Takeda Oncology, Cilag
OpenAlex ID: W1986565094
Cites: 11
Cited by: 1
Related to: 10